ICAHN School of Medicine At Mount Sinai

Lawrence Phillips, a non-smoker and lifelong runner, was diagnosed with lung cancer in 2008. After initial surgery and follow-up treatments, including chemotherapy and targeted therapy for his EGFR mutation, Phillips remains cancer-free at 82, continuing to work and exercise.

New research from Cincinnati Children’s suggests that eliminating animal milk alone may be as effective as a four-food elimination diet for treating pediatric eosinophilic esophagitis (EoE). The study, published in The Journal of Allergy and Clinical Immunology, found similar remission rates and symptom improvements between the two diets, supporting a simpler initial approach for children with EoE.

Aging immune system drives cancer growth via harmful inflammation, promoting pro-tumor macrophages. Anakinra, an anti-inflammatory drug, blocks these signals, potentially preventing cancer in older adults. Study suggests targeting aging immune system could reduce cancer risk.

Aging immune system spurs tumor growth, with anakinra potentially repurposed to block harmful signals, reducing cancer risk in older adults.

Empagliflozin, an SGLT2 inhibitor, safely and effectively reduces heart failure events and confers kidney-protective benefits in patients hospitalized for acute myocardial infarction, regardless of baseline kidney function, according to a Mount Sinai-led study presented at the European Society of Cardiology Congress.

Empagliflozin, an SGLT2 inhibitor, is safe and effective for treating heart attack patients, showing kidney-protective benefits and reducing heart failure events regardless of baseline kidney function, according to a Mount Sinai-led study presented at the European Society of Cardiology Congress.

Long-term ixekizumab treatment showed similar efficacy in challenging body areas of psoriasis over 5 years.

Finerenone reduced CV death and worsening HF risk by 16% in HF patients with mildly reduced or preserved ejection fraction, per FINEARTS-HF trial. Pooled analyses showed benefits of finerenone and MRAs in high-risk patients.

A phase 3 clinical trial for essential thrombocythemia patients has launched, investigating bomedemstat as a potential new treatment. The trial, named Shorespan-007, aims to compare bomedemstat to standard chemotherapy, hydroxyurea, and is expected to conclude in May 2029.

Mount Sinai team created a dataset and POND dashboard using NHANES data to personalize interventions for youth prediabetes and diabetes, identifying 27 risk-associated variables.